Merck & Co., Inc. (MRK) Stock Price & Analysis
Merck & Co., Inc. (MRK) fell 1.32% to USD 150.33 as of September 8, 2026 at 02:53 UTC, according to Nexqual real-time market data.
MRK last closed at USD 150.33; the session ranged USD 150.09–152.22 on volume of 4,298,143 shares. Market capitalization is —, with a 52-week range of USD 77.58–156.92 (NYQ). Source: Nexqual, September 8, 2026 at 02:53 UTC.
Key Statistics (as of September 8, 2026 at 02:53 UTC)
| Price | USD 150.33 |
|---|---|
| Change | ▼ 1.32% (down) |
| Previous Close | USD 150.33 |
| Open | USD 150.33 |
| Day Range | USD 150.09 – 152.22 |
| 52-Week Range | USD 77.58 – 156.92 |
| Volume | 4,298,143 shares |
| Market Cap | — |
| Exchange | NYQ |
Technical Analysis (MRK)
Nexqual's technical model rates MRK "STRONG BUY" based on 5 bullish and 0 bearish signals across 128 daily candles, as of September 8, 2026 at 02:53 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 63.09 (neutral) |
| vs SMA50 | Above (USD 134.59) |
| MACD | 5.49 (positive) |
From Merck & Co., Inc.'s Latest SEC 10-K Filing (filed 2026-02-24)
Key Strengths & Strategy (as disclosed to the SEC)
- Department of Health and Human Services (HHS) has stated that immunizations for all of the diseases covered by the previous immunization schedule will still be available to anyone who wants them through Affordable Care Act insurance plans and federal insurance programs, including Medicaid, the Children's Health Insurance Program, and the VFC program.
Partnerships
- The Company manufactures a hepatitis B vaccine ( Recombivax HB , Hepatitis B Vaccine [Recombinant]) and, subject to a collaboration agreement with Sanofi Pasteur MSD, co-promotes a hexavalent vaccine that includes a hepatitis B component ( Vaxelis, Diphtheria and Tetanus Toxoids and Acellular Pertussis, Inactivated Poliovirus, Haemophilus b Conjugate and Hepatitis B Vaccine).
- Product Approvals Set forth below is a summary of significant product approvals received by the Company in 2025 and, to date, in 2026. 4 Table of Contents 5 Table of Contents (1)      Keytruda Qlex is available in some markets as Keytruda SC . (2)     Being jointly developed and commercialized in a worldwide collaboration with AstraZeneca.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| PFE | Pfizer, Inc. | USD 28.45 | ▼ 1.96% |
| JNJ | Johnson & Johnson | USD 275.23 | ▲ 0.01% |
| PG | Procter & Gamble Company (The) | USD 146.44 | ▼ 0.81% |
| BMY | Bristol-Myers Squibb Company | USD 66.82 | ▼ 1.24% |
| VZ | Verizon Communications Inc. | USD 50.14 | ▼ 0.16% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 02:53 UTC. This page is informational and not investment advice.